Pandemic Response

With our heritage and unique capabilities, along with our global manufacturing network, we have systemized the process of preparing for influenza pandemic outbreaks and work with numerous governments to support their influenza vaccine pandemic preparedness needs. Our dual production platforms and MF59^® antigen-sparing technology⁴ underpin our commitment to rapidly supply pandemic influenza vaccines when needed.

_{Pictured: CSL Seqirus researcher in the lab in Massachusetts, USA}

We offer a portfolio of pre-pandemic and pandemic influenza vaccines through agreements signed with governments as well as with the World Health Organization. These agreements ensure that pandemic influenza dose capacity is reserved and can be deployed upon the declaration of a pandemic. Some governments have policies to protect first responders with early access to pandemic vaccine doses. Many of these governments rely on CSL Seqirus to provide pre-pandemic stockpiles of antigen and MF59^® adjuvant that could be quickly combined in the early phase of a global outbreak.

_{Pictured: CSL Seqirus manufacturing employees in Holly Springs, NC, USA}

In the event of an influenza pandemic, CSL Seqirus commits to a rapid and reliable response through the provision of reserved pandemic vaccine doses. Our pre-pandemic and pandemic influenza vaccines are licensed in a number of countries. We continue to test pre-pandemic candidate vaccines produced on our manufacturing platforms. Our ongoing projects are aimed at accelerating our response, via further surge capacity enhancement.

_{Pictured: CSL Seqirus researcher in Holly Springs, NC, USA}